Maxcyte (MXCT) Accumulated Expenses (2020 - 2026)

Maxcyte (MXCT) has 7 years of Accumulated Expenses data on file, last reported at $4.4 million in Q1 2026.

• Quarterly Accumulated Expenses fell 13.15% year-over-year to $4.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.4 million (down 13.15% YoY) and the FY2025 annual result came in at $7.8 million, down 5.9% from the prior year.
• Accumulated Expenses eased to $4.4 million in Q1 2026 per MXCT's latest filing, from $7.8 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $11.3 million in Q4 2023 and bottomed at $3.9 million in Q1 2022.
• The 5-year median for Accumulated Expenses is $7.8 million (2025), against an average of $7.3 million.
• The widest annual swing landed in 2023, when Accumulated Expenses surged 78.59%; it then fell 26.33% in 2024.
• Tracing MXCT's Accumulated Expenses over 5 years: stood at $8.3 million in 2022, then surged by 36.35% to $11.3 million in 2023, then slipped by 26.33% to $8.3 million in 2024, then dropped by 5.9% to $7.8 million in 2025, then sank by 44.05% to $4.4 million in 2026.
• Per Business Quant, the three latest MXCT Accumulated Expenses figures stand at $4.4 million (Q1 2026), $7.8 million (Q4 2025), and $8.3 million (Q3 2025).

Peer Comparison